CytoDyn Inc.

CYDY | OTC | CIK: 0001175680 | SIC: 2834 Pharmaceutical Preparations | active
Vancouver, Washington | Founded: 2002
CytoDyn Inc. is a clinical-stage biotechnology company focused on the development and potential commercialization of leronlimab (PRO 140), a humanized monoclonal antibody targeting the CCR5 receptor. The company is studying leronlimab for solid-tumor oncology indications, including microsatellite stable metastatic colorectal cancer and metastatic Triple-Negative Breast Cancer, and is also researching a long-acting version of leronlimab.
solid-tumor-oncologymetastatic-colorectal-cancermetastatic-triple-negative-breast-cancerclinical-stage-biotechnology
AI agents: Get this data as structured JSON (~200 tokens):
https://origin.rootz.global/api/company/CYDY
Profile | Timeline | SEC Filings | People

Products

NameTypeDescription
Leronlimab (PRO 140)platformHumanized monoclonal antibody targeting CCR5 receptor, studied for solid-tumor oncology including colorectal cancer and Triple-Negative Breast Cancer.

Partnerships

PartnerTypeDescription
Syneos HealthdevelopmentEngaged as CRO for Phase II trial of leronlimab in relapsed/refractory MSS metastatic colorectal cancer patients.
CBIZ CPAs P.C.strategicEngaged as independent registered public accounting firm for fiscal year ended May 31, 2025, replacing Marcum LLP.

SEC Filings

View all SEC EDGAR filings: EDGAR Company Page

Structured filing index: /api/company/CYDY/filings

Origin — Data Provenance
This profile was extracted from SEC EDGAR filings (PEM-signed by sec.gov).
Every API response includes a cryptographic origin leaf for chain-of-custody tracking.
AI Discovery Document | Registry Metrics | GitHub